We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

141 hedge funds and large institutions have $445M invested in Ocular Therapeutix in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 48 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $19M | Put options by funds: $9.56M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

2% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 48

5.24% less ownership

Funds ownership: 63.4% → 58.16% (-5.2%)

5% less funds holding

Funds holding: 149 → 141 (-8)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

35% less capital invested

Capital invested by funds: $685M → $445M (-$239M)

Holders
141
Holders Change
-8
Holders Change %
-5.37%
% of All Funds
2.47%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
16
Increased
49
Reduced
48
Closed
23
Calls
$19M
Puts
$9.56M
Net Calls
+$9.48M
Net Calls Change
-$3.85M

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$5.62M
2
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$4.85M
3
ACM
Altium Capital Management
New York
+$3.37M
4
Millennium Management
Millennium Management
New York
+$2.99M
5
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$20.2M
2
GPP
Great Point Partners
Connecticut
-$13M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$10.6M
4
AS
Altshuler Shaham
Israel
-$4.84M
5
EA
Emerald Advisers
Pennsylvania
-$4.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$3.27M -$2.9M -258,165 -44%
Goldman Sachs
27
Goldman Sachs
New York
$3.19M -$1.89M -167,930 -35%
Millennium Management
28
Millennium Management
New York
$2.81M +$2.99M +266,135 +1,757%
IC
29
Ikarian Capital
Texas
$2.77M -$1.6M -142,022 -34%
Charles Schwab
30
Charles Schwab
California
$2.51M +$15.9K +1,416 +0.6%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.46M +$313K +27,832 +13%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.46M -$909K -80,922 -25%
NA
33
Nottingham Advisors
New York
$1.94M – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
34
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.82M +$2.04M +181,600 New
Principal Financial Group
35
Principal Financial Group
Iowa
$1.46M +$6.08K +541 +0.4%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.43M +$24.7K +2,200 +2%
SM
37
Sabby Management
Florida
$1.42M +$1.38M +122,783 +639%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$1.15M +$100K +8,900 +8%
AS
39
Altshuler Shaham
Israel
$1.11M -$4.84M -431,009 -80%
Invesco
40
Invesco
Georgia
$1.06M +$201K +17,923 +20%
QP
41
Quilter Plc
United Kingdom
$979K – – –
EAM
42
Erste Asset Management
Austria
$971K +$292K +26,000 +37%
Tudor Investment Corp
43
Tudor Investment Corp
Connecticut
$947K +$1.06M +94,712 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$943K -$127K -11,298 -11%
RJA
45
Raymond James & Associates
Florida
$938K +$335K +29,818 +47%
CSS
46
Cubist Systematic Strategies
Connecticut
$914K +$754K +67,123 +277%
Brown Advisory
47
Brown Advisory
Maryland
$900K – – –
Marshall Wace
48
Marshall Wace
United Kingdom
$893K +$856K +76,221 +581%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$890K +$43.2K +3,845 +5%
CA
50
Cetera Advisors
Colorado
$869K +$976K +86,916 New
1
2
3 4 5

OCUL Hedge Fund Activity: Q3 2021 in Review

141 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2021, worth a combined $445M — down 35% from $685M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of OCUL and 16 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 49 added.

The largest buyer was Affinity Asset Advisors, adding an estimated $5.62M. The largest seller was Rubric Capital Management (New York), cutting an estimated $20.2M.

  • 141 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2021, down from 149 in Q2 2021.
  • Funds reported $445M of Ocular Therapeutix stock for Q3 2021, down 35% quarter-over-quarter.
  • 16 funds opened new Ocular Therapeutix positions in Q3 2021 and 23 closed out, a net change of -7 holders.
  • The largest Ocular Therapeutix buyer in Q3 2021 was Affinity Asset Advisors, an estimated $5.62M added.
  • The largest Ocular Therapeutix seller in Q3 2021 was Rubric Capital Management (New York), an estimated $20.2M sold.

Based on aggregated 13F filings for Q3 2021.